Skip to Content

Medpace Holdings Inc MEDP

Morningstar Rating
$402.81 −1.20 (0.30%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Narrow-Moat Medpace Benefits From Healthy Clinical Trial Outsourcing Demand; Positive Outlook

Medpace is a global, late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. The company was founded over 30 years ago in Cincinnati, Ohio. Its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia.

Price vs Fair Value

MEDP is trading at a 54% premium.
Price
$402.27
Fair Value
$528.00
Uncertainty
Medium
1-Star Price
$595.45
5-Star Price
$511.20
Economic Moat
Drtrqkc
Capital Allocation
Jvcdnvr

Bulls Say, Bears Say

Bulls

Medpace's small and midsized biopharma customers are very dependent on outsourced clinical trials since they do not have the capacity to run trials in-house.

Bears

Significant pullbacks to biotech funding or declines in outsourcing penetration rates could have a material impact on Medpace's growth.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MEDP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$404.01
Day Range
$401.72403.98
52-Week Range
$179.63419.05
Bid/Ask
$402.78 / $403.33
Market Cap
$12.39 Bil
Volume/Avg
14,542 / 266,956

Key Statistics

Price/Earnings (Normalized)
45.41
Price/Sales
6.81
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
1.16%

Company Profile

Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Mid Growth
Total Number of Employees
5,900

Competitors

Valuation

Metric
MEDP
FTRE
ICLR
Price/Earnings (Normalized)
45.4172.0823.96
Price/Book Value
22.192.052.94
Price/Sales
6.811.143.36
Price/Cash Flow
39.2829.2721.36
Price/Earnings
MEDP
FTRE
ICLR

Financial Strength

Metric
MEDP
FTRE
ICLR
Quick Ratio
0.591.521.16
Current Ratio
0.641.621.21
Interest Coverage
688.871.022.99
Quick Ratio
MEDP
FTRE
ICLR

Profitability

Metric
MEDP
FTRE
ICLR
Return on Assets (Normalized)
20.56%1.15%6.18%
Return on Equity (Normalized)
69.64%2.40%11.98%
Return on Invested Capital (Normalized)
48.77%3.06%10.27%
Return on Assets
MEDP
FTRE
ICLR
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
TMO
Thermo Fisher Scientific IncXyhzshtdzCbpcj$220.9 Bil
DHR
Danaher CorpGsbclbmtrYmsvcpk$184.0 Bil
IQV
IQVIA Holdings IncVkhkjkwxxPjpnkks$46.0 Bil
IDXX
IDEXX Laboratories IncGqrljtdkmQmdpgr$44.8 Bil
A
Agilent Technologies IncGzzxhjrgQzl$43.2 Bil
MTD
Mettler-Toledo International IncCtsrgljztLplwf$28.6 Bil
ICLR
Icon PLCHqbchvwzTbwhzp$27.2 Bil
ILMN
Illumina IncXsdsgsfFzwdyzy$22.0 Bil
WAT
Waters CorpCbfyhldrwJmby$20.4 Bil
LH
Laboratory Corp of America HoldingsPlwrmdssHnkkjps$18.2 Bil

Sponsor Center